Evidence map›Paper›PMID 37610095›Full record

ArticleJournal of cellular and molecular medicine2023

Acid ground nano-realgar processed product inhibits breast cancer by inducing mitophagy via the p53/BNIP3/NIX pathway.

Jiahui Fang, Xue Zou, Ling Gong, Juan Xi, Yi Liu, Xiaoli Yang, Xiuqiao Zhang, Chun Gui

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiahui FangCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Xue ZouCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Ling GongCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Juan XiCollege of Inspection, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Yi LiuCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Xiaoli YangCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Xiuqiao ZhangCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Chun GuiCollege of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, China.ORCID 0000-0003-2032-2501
Hubei University of Chinese Medicine · CNHubei University of Medicine · CN

Funding

Scientific Research Foundation of Education Department of Hubei Province in China Q20202004Traditional Chinese Medicine high-level key discipline construction project of National Administration of Traditional Chinese Medicine (2023)-Medicinal Mineralogy
6 · The paper itself

Abstract

Breast cancer is a highly prevalent malignancy with the first morbidity and the primary reason for female cancer-related deaths worldwide. Acid ground nano-realgar processed product (NRPP) could inhibit breast cancer cell proliferation and induce autophagy in our previous research; however, the underlying mechanisms are still unclear. Therefore, this research aimed to verify whether NRPP induces breast cancer mitophagy and explore the mitophagy-mediated mechanism. Primarily, rhodamine-123 assay and transmission electron microscopy were applied to detect mitochondrial membrane potential (MMP) and ultrastructural changes in the MDA-MB-435S cells, respectively. Mito-Tracker Green/Lyso-Tracker Red staining, western blot, immunofluorescence and RT-PCR were used to explore molecular mechanisms of NRPP-induced mitophagy in vitro. MDA-MB-435S breast cancer xenograft models were established to assess the activity and mechanisms of NRPP in vivo. Our results showed that NRPP decreased MMP and increased autophagosome numbers in MDA-MB-435S cells and activated mitophagy. Furthermore, mitophagy was consolidated because mitochondria and lysosomes colocalized phenomenology were observed, and the expression of LC3II/I and COXIV was upregulated. Additionally, we found the p53/BNIP3/NIX pathway was activated. Finally, NRPP inhibited tumour growth and downregulated the levels of TNF-α, IL-1β and IL-6. Necrosis, damaged mitochondria and autophagosomes were observed in xenograft tumour cells, and proteins and mRNA levels of LC3, p53, BNIP3 and NIX were increased. Overall, NRPP inhibited MDA-MB-435S cell proliferation and tumour growth by inducing mitophagy via the p53/BNIP3/NIX pathway. Thus, NRPP is a promising candidate for breast cancer treatment.

Indexed as

Breast NeoplasmsMitophagyAutophagyFemaleHumansMembrane ProteinsMitochondriaMitochondrial ProteinsProto-Oncogene ProteinsTumor Suppressor Protein p53BNIP3 protein, humanMembrane ProteinsMitochondrial ProteinsProto-Oncogene ProteinsTumor Suppressor Protein p53acid ground nano-realgar processed productbreast cancerMDA-MB-435S cellmitophagyp53/BNIP3/NIX

Identifiers

PMID37610095
PMCPMC10660646
OpenAlexW4386084987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.